There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...

UW Health's Dr. Bill Hartman discusses a new study on Ozempic and alcohol cravings. For the first time since the start of the pandemic, flu deaths now outnumber COVID-19 deaths.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year. By Eshe Nelson Reporting from London Novo Nordisk ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Europe's most valuable company said its sales rose 25 percent to 290.4 billion Danish ... people are now benefiting from our treatments". Ozempic, which accounts for 41 per cent of the company's ...